Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis
Figure 2
Immune and clinical responses in prostate and renal cell cancer (RCC) patients.
(A) Induction of tumor antigen specific cellular or humoral immune responses. An immune response was considered positive when at least one of the conducted assays was positive. (B) Analysis of objective response (black columns) and clinical benefit rate (CBR; grey columns). CR, complete response; PR, partial response; MR, mixed response; SD, stable disease.